LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection.

Amini Pouya, Maryam / Afshani, Seyyedeh Maryam / Maghsoudi, Armin Salek / Hassani, Shokoufeh / Mirnia, Kayvan

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

2020 Volume 28, Issue 2, Page(s) 745–764

Abstract: Objectives: There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount ... ...

Abstract	Objectives: There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount of available information for useful interpretation. Evidence acquisition: We searched databases with different keywords and search strategies that focus on virulence and pathophysiology of COVID-19. The present review has aimed to gather and categorize all implemented drugs based on the susceptible virulence mechanisms, and the pathophysiological events in the host cells, discussing and suggesting treatments. Results: As a result, the COVID-19 lifecycle were categorized as following steps: "Host Cell Attachment" which is mainly conducted with ACE Conclusion: The treatment protocol would be occasional based on the stage of the infection and the patient situation. The cocktail of medicines, which could affect almost all mentioned stages of COVID-19 disease, might be vital for patients with severe phenomena. The classification of the possible mechanism of medicines based on COVID-19 pathogenicity.
MeSH term(s)	Animals ; COVID-19/physiopathology ; COVID-19/virology ; Humans ; Inflammation/drug therapy ; Inflammation/physiopathology ; Inflammation/virology ; SARS-CoV-2/drug effects ; SARS-CoV-2/pathogenicity ; COVID-19 Drug Treatment
Keywords	covid19
Language	English
Publishing date	2020-07-30
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2129183-4
ISSN	2008-2231 ; 1560-8115
ISSN (online)	2008-2231
ISSN	1560-8115
DOI	10.1007/s40199-020-00359-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

Amini Pouya, Maryam / Afshani, Seyyedeh Maryam / Maghsoudi, Armin Salek / Hassani, Shokoufeh / Mirnia, Kayvan

DARU Journal of Pharmaceutical Sciences ; ISSN 2008-2231

2020

Keywords	covid19
Language	English
Publisher	Springer Science and Business Media LLC
Publishing country	us
Document type	Article ; Online
DOI	10.1007/s40199-020-00359-4
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The association of upper respiratory infections with neuro-radiological course and attack rate of multiple sclerosis: Results from a large prospective cohort.

Ghasemi, Moein / Farazandeh, Dorreh / Amini, Behnam / Sedaghat, Mona / Najafi, Anahita / Khayatzadeh Kakhki, Simin / Torabi, Pouya / Jafarimehrabady, Niloofar / Bitaraf, Ali / Shariati, Houria / Gholampour, Golsa / Kazemi, Saminnaz / Naser Moghadasi, Abdorreza / Vajihinejad, Maryam

Multiple sclerosis journal - experimental, translational and clinical

2023 Volume 9, Issue 3, Page(s) 20552173231196992

Abstract: Background: Although upper respiratory infections (URIs) are linked to multiple sclerosis (MS) attacks, SARS-COV2 has not been compared to URIs for attack rates.: Objectives: This study aimed to evaluate the attack rate and the results of ... ...

Abstract	Background: Although upper respiratory infections (URIs) are linked to multiple sclerosis (MS) attacks, SARS-COV2 has not been compared to URIs for attack rates. Objectives: This study aimed to evaluate the attack rate and the results of neuroimaging in MS patients with URIs caused by COVID-19 and non-COVID-19 infections (NC-URI). Methods: From May 2020 to April 2021, we followed 362 patients with relapsing-remitting MS in a prospective cohort design. Patients were monitored regularly every 12 weeks; an magnetic resonance imaging (MRI) scan was performed at enrollment and every time a relapse occurred. Poisson analysis was used to determine exacerbation rate ratios (RR) and the MRI parameters were tested using chi-square analysis. Results: 347 patients with an average age of 38 and a female ratio of 86% were included. A RR of 2.24 ( Conclusion: COVID-19 has been shown to increase the risk of MS exacerbations, like other viral URIs.
Language	English
Publishing date	2023-09-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	2841884-0
ISSN	2055-2173 ; 2055-2173
ISSN (online)	2055-2173
ISSN	2055-2173
DOI	10.1177/20552173231196992
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection

Amini Pouya, Maryam / Afshani, Seyyedeh Maryam / Maghsoudi, Armin Salek / Hassani, Shokoufeh / Mirnia, Kayvan

Abstract: OBJECTIVES: There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount ... ...

Abstract	OBJECTIVES: There are several types of research on the COVID-19 disease which have been conducting. It seems that prevailing over the pandemic would be achieved only by mastering over the virus pathophysiology. We tried to categorize the massive amount of available information for useful interpretation. EVIDENCE ACQUISITION: We searched databases with different keywords and search strategies that focus on virulence and pathophysiology of COVID-19. The present review has aimed to gather and categorize all implemented drugs based on the susceptible virulence mechanisms, and the pathophysiological events in the host cells, discussing and suggesting treatments. RESULTS: As a result, the COVID-19 lifecycle were categorized as following steps: "Host Cell Attachment" which is mainly conducted with ACE2 receptors and TMPRSS2 from the host cell and Spike (S) protein, "Endocytosis Pathway" which is performed mainly by clathrin-mediated endocytosis, and "Viral Replication" which contains translation and replication of RNA viral genome. The virus pathogenicity is continued by "Inflammatory Reactions" which mainly caused moderate to severe COVID-19 disease. Besides, the possible effective therapeutics' mechanism and the pharmaceutical agents that had at least one experience as a preclinical or clinical study on COVID-19 were clearly defined. CONCLUSION: The treatment protocol would be occasional based on the stage of the infection and the patient situation. The cocktail of medicines, which could affect almost all mentioned stages of COVID-19 disease, might be vital for patients with severe phenomena. The classification of the possible mechanism of medicines based on COVID-19 pathogenicity.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #688666
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.

Mohraz, Minoo / Vahdat, Katayoun / Ghamari, Seyyed-Hadi / Abbasi-Kangevari, Mohsen / Ghasemi, Erfan / Ghabdian, Yasaman / Rezaei, Negar / Pouya, Maryam Amini / Abdoli, Asghar / Malekpour, Mohammad-Reza / Koohgir, Keyvan / Saeedi Moghaddam, Sahar / Tabarsi, Payam / Moghadami, Mohsen / Khorvash, Farzin / Khodashahi, Rozita / Salehi, Mohammadreza / Hosseini, Hamed

BMJ (Clinical research ed.)

2023 Volume 382, Page(s) e070464

Abstract: Objective: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine.: Design: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.: Setting: In six cities ... ...

Abstract	Objective: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine. Design: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. Setting: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan. Participants: 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1. Intervention: 5 µg vaccine or placebo with the interval of 28 days. Main outcome measures: Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial. Results: 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41 922 adverse events were reported: 28 782 (68.7%) were adverse reactions, of which 19 363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant. Conclusions: A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised. Trial registration: Iranian Registry of Clinical Trials, IRCT20201202049567N3. Funding: Shifa-Pharmed Industrial Group.
MeSH term(s)	Adult ; Female ; Humans ; Male ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Iran/epidemiology ; SARS-CoV-2 ; Vaccines, Inactivated
Chemical Substances	COVID-19 Vaccines ; Vaccines, Inactivated
Language	English
Publishing date	2023-09-21
Publishing country	England
Document type	Randomized Controlled Trial ; Multicenter Study ; Journal Article
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj-2023-070464
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Application of disaccharides alone and in combination, for the improvement of stability and particle properties of spray-freeze dried IgG.

Daneshmand, Behnaz / Faghihi, Homa / Amini Pouya, Maryam / Aghababaie, Shabnam / Darabi, Majid / Vatanara, Alireza

Pharmaceutical development and technology

2018 Volume 24, Issue 4, Page(s) 439–447

Abstract: Purpose: Spray-freeze drying (SFD) is a recently applied method to develop pharmaceutical powders. This study aimed to analyze the competence of Trehalose, Mannitol, Lactose, and Sorbitol instability and aerosolization of Immunoglobulin G (IgG) via SFD.! ...

Abstract	Purpose: Spray-freeze drying (SFD) is a recently applied method to develop pharmaceutical powders. This study aimed to analyze the competence of Trehalose, Mannitol, Lactose, and Sorbitol instability and aerosolization of Immunoglobulin G (IgG) via SFD. Methods: Induced soluble aggregates were quantified at 0 and 3 months, and 45 °C using size-exclusion chromatography. Conformation and thermogravimetric assessments were done by Fourier transform infrared spectroscopy and differential scanning calorimetry. Laser light scattering was performed to determine the particle sizes. Aerodynamic features were characterized by twin stage impinger and scanning electron microscopy. Results: Although sugars/polyols preferably stabilized IgG following the process, storage stabilization was achieved in Trehalose, Trehalose-Lactose, Lactose, and Trehalose-Mannitol-based powders with soluble aggregates <5%. The conformation of antibody was preserved with β sheet content from 66.28% to 76.37%. Particle sizes ranged from 5.23 to 8.12 µm. Mannitol exhibited the best aerodynamic behavior, fine particle fraction (FPF: 70%) but high degree of protein aggregation during storage. Conclusions: SFD could favorably stabilize antibody using Trehalose and its combination with Lactose and Mannitol, and also, Lactose alone. Sorbitol disturbed IgG powder recovery. Incorporation of other types of excipient is required for efficient respiratory delivery of IgG molecules.
MeSH term(s)	Chemistry, Pharmaceutical/methods ; Disaccharides/chemistry ; Drug Combinations ; Drug Compounding ; Drug Stability ; Excipients/chemistry ; Freeze Drying/methods ; Immunoglobulin G/chemistry ; Mannitol/chemistry ; Particle Size ; Trehalose/chemistry
Chemical Substances	Disaccharides ; Drug Combinations ; Excipients ; Immunoglobulin G ; Mannitol (3OWL53L36A) ; Trehalose (B8WCK70T7I)
Language	English
Publishing date	2018-09-27
Publishing country	England
Document type	Journal Article
ZDB-ID	1331774-x
ISSN	1097-9867 ; 1083-7450
ISSN (online)	1097-9867
ISSN	1083-7450
DOI	10.1080/10837450.2018.1507039
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5043: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: COVID-19 in Patients with Rheumatic Disease Using Immunomodulatory Drugs: Imaging Findings and Predictors of Hospitalization.

Azizi, Hossein / Karimi, Hanie / Kazemi, Mahdi / Rezaei, Somaye Sadat / Parsaei, Amirhossein / Aghaali, Mohammad / Vafaeimanesh, Jamshid / Torabi, Pouya / Amini, Behnam / Masoumi, Maryam

Rheumatology and therapy

2022 Volume 10, Issue 1, Page(s) 249–259

Abstract: Introduction: SARS-CoV-2 causes more severe symptoms in most chronic diseases, and rheumatic disease is no exception. This study aims to investigate whether there is an association between the use of immunomodulatory medications, including conventional ... ...

Abstract	Introduction: SARS-CoV-2 causes more severe symptoms in most chronic diseases, and rheumatic disease is no exception. This study aims to investigate whether there is an association between the use of immunomodulatory medications, including conventional disease-modifying agents (csDMARDs), glucocorticoids, and biologic DMARDs, and outcomes such as hospitalization and lung involvement in patients with rheumatic disease with COVID-19. Methods: We performed a cross-sectional study on 177 COVID-19 cases with rheumatologic diseases using immunomodulatory drugs as their regular treatment. All patients were evaluated regarding their initial chest computed tomography (CT) scan, COVID-19 symptoms, and comorbidities. We ran predictive models to find variables associated with chest CT-scan involvement and hospitalization status. Results: CT findings showed lung involvement in 87 patients with chest CT-scan severity score (C-ss) of less than 8 in 59 (33%) and more than 8 in 28 (16%) of our patients. Of all patients, 76 (43%) were hospitalized. Hospitalized patients were significantly older and had more comorbidities ( Conclusions: This study found that advanced age and comorbidities, similar to the general population, are risk factors for hospitalization in patients with COVID-19 with rheumatic disorders. Administration of csDMARDs, older age, and pulmonary disorders were linked to increased risk of COVID-19 pneumonia in these individuals.
Language	English
Publishing date	2022-12-02
Publishing country	England
Document type	Journal Article
ZDB-ID	2783278-8
ISSN	2198-6584 ; 2198-6576
ISSN (online)	2198-6584
ISSN	2198-6576
DOI	10.1007/s40744-022-00508-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.

Mohraz, Minoo / Salehi, Mohammadreza / Tabarsi, Payam / Abbasi-Kangevari, Mohsen / Ghamari, Seyyed-Hadi / Ghasemi, Erfan / Amini Pouya, Maryam / Rezaei, Negar / Ahmadi, Naser / Heidari, Kazem / Malekpour, Mohammad-Reza / Nasiri, Mojtaba / Amirzargar, Ali Akbar / Saeedi Moghaddam, Sahar / Larijani, Bagher / Hosseini, Hamed

BMJ open

2022 Volume 12, Issue 4, Page(s) e056872

Abstract: Objective: Assessing safety and immunogenicity of an inactivated whole virus particle vaccine.: Design: Single-centre, double-blind, randomised, placebo-controlled, phase I (stage I: 18-50, stage II: 51-75 years), phase II (18-75 years) clinical ... ...

Abstract	Objective: Assessing safety and immunogenicity of an inactivated whole virus particle vaccine. Design: Single-centre, double-blind, randomised, placebo-controlled, phase I (stage I: 18-50, stage II: 51-75 years), phase II (18-75 years) clinical trials. Setting: 29 December 2020 to 22 April 2021. Participants: Stage I-phase I: 56 participants; stage II-phase I: 32; phase II: 280. Intervention: During stage I, participants randomly (3:3:1) received 3 µg, 5 µg vaccine or placebo in a 14-day interval. Participants in stage II received two shots of 5 µg vaccine or placebo (3:1). In phase II, participants received 5 µg vaccine or placebo (4:1) in a 28-day interval. Primary and secondary outcome measures: Safety assessment and immunogenicity assessment via antibody response and conventional virus neutralisation test (cVNT). Results: All adverse events (AEs) were mild or moderate and transient in both phase I and phase II, and no AEs of special interest were reported. The seroconversion-rate of neutralising, antireceptor binding-domain (RBD) and anti-spike-glycoprotein (anti-S) antibodies 14-days after second dose of 5 µg vaccine in stage I was 70.8% (95% CI 48.9% to 87.4%), 87.5% (95% CI 67.6% to 97.3%), 91.7% (95% CI 73.0% to 99.0%). The antibody titres increased more among 5 µg than 3 µg. The corresponding rates for 3 µg vaccine were 45.8% (95% CI 25.6% to 67.2%), 54.2% (95% CI 32.8% to 74.5%) and 70.8% (95% CI 48.9% to 87.4%), respectively. In stage II, 100% (95% CI 84.6% to 100%), 86.4% (95% CI 65.1% to 97.1%) and 86.4% (95% CI 65.1% to 97.1%) of participants seroconverted for neutralising, anti-RBD and anti-S antibodies. In phase II, the seroconversion rate of neutralising-antibody was 82.8% (95% CI 77.0% to 87.6%), anti-RBD 77.0% (95% CI 70.7% to 82.6%) and anti-S 79.9% (95% CI 73.8% to 85.1%) on day 42. In the cVNT, the sera at 1/64 times dilution would neutralise SARS-CoV-2 among 91.7%, 77.3% and 82.5% of vaccinated participants in phase I-stage I, phase I-stage II and phase II clinical trials, respectively. Conclusions: These results support further evaluation of this inactivated whole virus particle vaccine. Trial registration numbers: IRCT20201202049567N1 and IRCT20201202049567N2 for phase I and IRCT20201202049567N3 for phase II.
MeSH term(s)	Adolescent ; Adult ; Aged ; Antibodies, Viral ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; Double-Blind Method ; Humans ; Middle Aged ; SARS-CoV-2 ; Vaccines, Inactivated/adverse effects ; Virion ; Young Adult
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; Vaccines, Inactivated
Language	English
Publishing date	2022-04-08
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-056872
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Spray-Freeze Drying: a Suitable Method for Aerosol Delivery of Antibodies in the Presence of Trehalose and Cyclodextrins.

Pouya, Maryam Amini / Daneshmand, Behnaz / Aghababaie, Shabnam / Faghihi, Homa / Vatanara, Alireza

AAPS PharmSciTech

2018 Volume 19, Issue 5, Page(s) 2247–2254

Abstract: We aimed to prepare spray-freeze-dried powder of IgG considering physicochemical stability and aerodynamic aspects. Spray-freeze drying (SFD) exposes proteins to various stresses which should be compensated by suitable stabilizers. The competence of ... ...

Abstract	We aimed to prepare spray-freeze-dried powder of IgG considering physicochemical stability and aerodynamic aspects. Spray-freeze drying (SFD) exposes proteins to various stresses which should be compensated by suitable stabilizers. The competence of cyclodextrins (CDs), namely beta-cyclodextrin (βCD) and hydroxypropyl βCD (HPβCD), at very low concentrations, was investigated in the presence of separate mannitol- and trehalose-based formulations. Spray-freeze-dried preparations were quantified in terms of monomer recovery and conformation by size exclusion chromatography (SEC-HPLC) and Fourier transform infrared (FTIR) spectroscopy, respectively. Differential scanning calorimetry (DSC) and X-ray diffractometry (XRD) were employed to identify the thermal characteristics of powders. Particle morphology was visualized by scanning electron microscopy (SEM). Aerodynamic behavior of powders was checked through an Anderson cascade impactor (ACI). Although all formulations protected antibody from aggregation during the SFD process (aggregation < 1%), mannitol-containing ones failed upon the storage (19.54% in the worst case). Trehalose-HPβCD incomparably preserved the formulation with fine particle fraction (FPF) of 51.29%. Crystallization of mannitol resulted in IgG destabilization upon storage. Although employed concentration of CDs is too low (less than 50:1 molar ratio to protein), they successfully served as stabilizing agents in SFD with perfect improvement in aerosol functionality. Graphical Abstract ᅟ.
MeSH term(s)	Aerosols ; Cyclodextrins/chemistry ; Drug Stability ; Freeze Drying/methods ; Immunoglobulin G/chemistry ; Powders/chemistry ; Trehalose/chemistry
Chemical Substances	Aerosols ; Cyclodextrins ; Immunoglobulin G ; Powders ; Trehalose (B8WCK70T7I)
Language	English
Publishing date	2018-05-08
Publishing country	United States
Document type	Journal Article
ISSN	1530-9932
ISSN (online)	1530-9932
DOI	10.1208/s12249-018-1023-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Oral health-related quality of life in rheumatoid arthritis: a comparative analysis.

Parsaei, Amirhossein / Mehdipour, Aida / Ghadimi, Hamidreza / Mohammadi Kooshki, Ashkan / Shajari, Parisa / Masoumi, Maryam / Torabi, Pouya / Azizi, Hossein / Amini, Behnam / Karimi, Hanie / Dehghanbanadaki, Hojat / Aghaali, Mohammad / Moradi, Soroush

BMC rheumatology

2022 Volume 6, Issue 1, Page(s) 61

Abstract: Background: Compared to the healthy population, the psychological impact of rheumatoid arthritis(RA) on patients' lives could dramatically lower their oral health-related quality of life (OHRQoL). Our goal is to analyze OHRQoL in RA patients and look ... ...

Abstract	Background: Compared to the healthy population, the psychological impact of rheumatoid arthritis(RA) on patients' lives could dramatically lower their oral health-related quality of life (OHRQoL). Our goal is to analyze OHRQoL in RA patients and look into the role of disease activity, dental health index, and Temporomandibular disorders score in maintaining their oral health. Methods: In a cross-sectional comparative study, we compared a sample of 40 RA patients with 40 age- and gender-matched healthy controls in terms of oral health and OHRQoL. Temporomandibular disorders (TMD), number of decayed, filled, or missing teeth (DMFT), and Oral Health Impact Profile (OHIP) were among the oral health factors studied (OHIP-14). This study also looked at the link between the RA disease activity score (DAS28) and oral health factors. Results: RA patients had a significantly higher mean (poorer OHRQol) than healthy controls in total oral function, total psychosocial impact, OHIP-14 sum score, OHIP-14 extent score, TMD score and the number of missed teeth (Mann-Whitney U test, P-value < 0.05). After adjustment for DMFT, only the oral function score of OHIP-14 had a significant correlation with disease activity (Mann-Whitney U test, P-value < 0.05). The TMD sum score significantly correlated with disease activity regardless of adjustment for DMFT (Spearman's Correlation test, P-value < 0.05 for both). The number of decayed teeth and missed teeth showed a positive correlation with increased disease activity (Coefficient = 0.239 and 0.245, P-value < 0.05 for both). Conclusions: Patients with RA are less satisfied with their oral health than healthy controls. In RA patients, the number of missing teeth and temporomandibular disorders was substantially greater, and the number of missing teeth and temporomandibular diseases increased significantly with increased disease activity. Although OHRQoL was inversely connected with RA activity, after correcting for decaying, missing, and filled teeth, only the oral function score of OHIP-14 exhibited a slight connection to DAS28.
Language	English
Publishing date	2022-10-18
Publishing country	England
Document type	Journal Article
ZDB-ID	2918121-5
ISSN	2520-1026 ; 2520-1026
ISSN (online)	2520-1026
ISSN	2520-1026
DOI	10.1186/s41927-022-00292-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito